Poland· PL-100436059

Amaplantis

A brak product containing plantaginis lanceolatae folii extractum fluidum, registered in Poland by Zakład Farmaceutyczny "Amara" Sp. z o.o..

ATC BRAK

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAmaplantisATCBRAKREGISTER NO.PL-100436059PACKS LISTED1CHECKEDSeptember 27, 2026

The record

At a glance

URPL (Poland)
Active substance
Plantaginis lanceolatae folii extractum fluidum
Manufacturer
Zakład Farmaceutyczny "Amara" Sp. z o.o.
Country
Poland (PL)
ATC code
BRAK
ATC class
BRAK
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05901315022099

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a181c1b7-9f7c-449f-8c0f-3ee3414c3053
GET /v1/drugs/a181c1b7-9f7c-449f-8c0f-3ee3414c3053?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Syrop",
  "source": "urpl",
  "strength": "150 mg/ml",
  "packaging": "05901315022099 ¦ OTC ¦ 164139\n1 butelka 125 g",
  "substance": "Plantaginis lanceolatae folii extractum fluidum 0.15 g/ml",
  "common_name": "Plantaginis lanceolatae folii extractum fluidum",
  "pl_product_id": "100436059",
  "pozwolenie_nr": "29839",
  "auth_procedure": "NAR",
  "authorisation_validity": "2031-07-13"
}

See everything about plantaginis lanceolatae folii extractum fluidum.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.